Saxol (2024)
法国生物科技公司Saxol近期公布其核心项目SAXOL的最新进展。该项目基于一项关键发现：新型化合物Carba1能与经典抗癌药物紫杉醇（Taxol®）产生协同作用。
研究数据显示，Carba1的加入可在保持紫杉醇原有疗效的同时，显著降低其所需剂量。这一特性有望直接减轻紫杉醇治疗带来的毒副作用，改善患者耐受性。
此外，Carba1还被证实能激活体内某种代谢酶，从而产生神经保护效应。这对于预防或缓解紫杉醇常见的剂量限制性神经毒性具有重要临床意义。
该项目目前处于临床前开发阶段，其双效机制——既增强化疗药物疗效又降低其神经毒性——为优化现有癌症治疗方案提供了新思路。
Project SAXOL: A Novel Combination Therapy Aims to Enhance Cancer Treatment and Reduce Neurotoxicity
A new therapeutic project, SAXOL, is based on the discovery of a molecule called Carba1, which works synergistically with the widely used chemotherapy drug Taxol® (paclitaxel). The core innovation is that Carba1 allows for a significant reduction in the required dose of Taxol while maintaining its full therapeutic efficacy against cancer.
Beyond this dose-sparing effect, Carba1 activates a key metabolic enzyme, triggering an additional neuroprotective mechanism. This addresses a major clinical drawback of Taxol, which is its dose-limiting neurotoxicity—a common and often debilitating side effect for patients. The SAXOL approach therefore aims to deliver a dual benefit: preserving anti-cancer effectiveness while actively protecting the nervous system from chemotherapy-induced damage.
Le projet SAXOL repose sur la découverte de Carba1 qui agit en synergie avec le Taxol® permettant d’en diminuer les doses tout en maintenant son efficacité thérapeutique. Il active également une enzyme du métabolisme, ce qui exerce un effet neuroprotecteur.
Saxol is a French biotech project that enhances the cancer drug Taxol® by allowing lower doses with maintained efficacy while also providing neuroprotective effects.
Saxol Project — A biotech/pharma research project, based in France.
Taxol® (Bristol Myers Squibb) — A widely used chemotherapy drug.
Monitor — Early-stage project with promising dual-action (chemo-enhancer and neuroprotector) that could impact oncology care if clinical development succeeds.
No companies linked yet